119th Congress · introduced in the Senate · Jul 24, 2025
Equitable Community Access to Pharmacist Services Act
Official title from Congress.gov
Latest action (Jul 24, 2025): Read twice and referred to the Committee on Finance. (text: CR S4701)
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in Senate (Jul 24, 2025)
Equitable Community Access to Pharmacist Services Act
This bill provides for permanent coverage under Medicare of certain pharmacist services.
Specifically, the bill provides for permanent coverage of testing and treatment services provided by pharmacists relating to (1) COVID-19, influenza, respiratory syncytial virus (RSV), and streptococcal pharyngitis (strep throat); and (2) other public health needs in relation to a declared public health emergency. (Similar authorities were temporarily granted during the COVID-19 public health emergency.) Such services must be provided in accordance with the applicable state laws governing pharmacists' scope of practice.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Finance. (text: CR S4701)
Introduced in Senate
Actions from Congress.gov, newest first.
Health care costs and insurance · Health care coverage and access · Medicare · Prescription drugs
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
125 citations; showing the 25 most recently posted.
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS · lobbying firm or registrant: AMERICAN COLLEGE OF EMERGENCY PHYSICIANS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$393,240
Spent on own lobbying
…to address the 2025 Medicare Physician Fee Schedule cuts and increaser support for physicians and other practitioners in adjusting to Medicare payment changes S. 2426-Ensuring Community Access to Pharmacist Services Act (ECAPS) Act, to amend title XVIII of the Social Security Act to provide pharmacy payment of certain servic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CVS HEALTH (AND SUBSIDIARIES) · lobbying firm or registrant: CVS HEALTH (AND SUBSIDIARIES)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Pharmacy
$2,040,000
Spent on own lobbying
Issues related to retail pharmacy, drug pricing, and women's health. H.R. 3164 - The Main Street Pharmacy Access Act S. 2426 - The Equitable Community Access to Pharmacist Services Act H.R. 5031, The Preserving Patient Access to Long-Term Care Pharmacies Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SENIOR CARE PHARMACY COALITION · lobbying firm or registrant: SENIOR CARE PHARMACY COALITION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
…serving Patient Access to Long-Term Care Pharmacies Act. H.R. 8800 / S. 4784 National Defense Authorization Act for Fiscal Year 2027 (FY2027 NDAA). H.R. 3164 / S. 2426 Ensuring Community Access to Pharmacist Services Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SENIOR CARE PHARMACY COALITION · lobbying firm or registrant: SENIOR CARE PHARMACY COALITION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$320,000
Spent on own lobbying
…serving Patient Access to Long-Term Care Pharmacies Act. H.R. 8800 / S. 4784 National Defense Authorization Act for Fiscal Year 2027 (FY2027 NDAA). H.R. 3164 / S. 2426 Ensuring Community Access to Pharmacist Services Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · lobbying firm or registrant: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$250,000
Spent on own lobbying
The Main Street Pharmacy Access Act/Ensuring Community Access to Pharmacist Services Act (H.R. 3164/S. 2426), including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUTTER HEALTH · lobbying firm or registrant: VENABLE LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
…duate medical education; Artificial intelligence; RESULTS Act (H.R. 5269 / S. 2761); Equitable Community Access to Pharmacist Services (ECAPS) Act (H.R. 3164 / S. 2426); 340B PATIENTS Act (H.R. 4581 / S. 2372); CONNECT for Health Act (H.R. 4206 / S. 1261); H.R. 1708 / S. 1087 Rebuild America's Healthcare Schools Act of 2025;…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CENCORA, INC. · lobbying firm or registrant: CENCORA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$405,804
Spent on own lobbying
…g Community Access to Pharmacist Services Act (H.R. 3164)/ Main Street Pharmacy Access Act (H.R. 3164)/ Equitable Community Access to Pharmacist Services Act (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Protecting Patient Access to Cancer and Complex Therapies Act 2…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CENCORA, INC. · lobbying firm or registrant: CENCORA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$405,804
Spent on own lobbying
…rtages Ensuring Seniors Access to Critical Medications Act/ Main Street Pharmacy Access Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA) Support for Fair Pharmacy Reimbursement
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CENCORA, INC. · lobbying firm or registrant: BALLARD SPAHR LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Extend payment increase under Medicare's physician fee schedule. Reimbursement policies impacting drug shortages Preventing and Mitigating Generic Drug Shorta…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CENCORA, INC. · lobbying firm or registrant: BALLARD SPAHR LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$50,000
Paid to lobbying firm
…ng and Mitigating Generic Drug Shortages Ensuring Seniors Access to Critical Medications Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN MEDICAL ASSOCIATION · lobbying firm or registrant: AVENUE SOLUTIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; H.R. 8163/S. 5180, Provider Reimbursement Stability Act; Issues related to Provider Reimbursement Stabi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
KROGER CO · lobbying firm or registrant: THE KROGER CO.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$360,000
Spent on own lobbying
H.R.6199/S.3934 - Medical Nutrition Therapy Act of 2025; H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to TrumpRx; Issues related to Nutrition and Wellness events.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHAIN DRUG STORES · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHAIN DRUG STORES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$480,000
Spent on own lobbying
…Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Retail Crime Act S. 2426 Equitable Community Access to Pharmacist Services Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Me…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CARDINAL HEALTH INC · lobbying firm or registrant: CARDINAL HEALTH, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$400,000
Spent on own lobbying
…Therapies Act; H.R. 5031/S. 3159, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164, Ensuring Community Access to Pharmacist Services Act; S. 2426, Equitable Community Access to Pharmacist Services Act, Education around issues facing independent physicians, including, S.3822, the Break Up Big Medicine Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALBERTSONS COMPANIES INC. · lobbying firm or registrant: COGENT STRATEGIES LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$130,000
Paid to lobbying firm
- Issues related to PBM reform - Issues related to Food is Medicine - Issues related to food labeling and packaging - H.R. 3164, Main St. Pharmacy Act - S. 2426, Equitable Community Access to Pharmacist Services Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALBERTSONS COMPANIES, INC. · lobbying firm or registrant: ALBERTSONS COMPANIES, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$360,000
Spent on own lobbying
Issues related to PBM Reform, Food is Medicine, and food labeling and packaging. H.R. 3164, Main St. Pharmacy Act. S. 2426, Equitable Community Access to Pharmacist Services Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
FUTURE OF PHARMACY COALITION LLC · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
H.R.3164/S.2426, Advance the Ensuring Access to Pharmacist Services Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · lobbying firm or registrant: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$3,203,049
Spent on own lobbying
S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOMERIEUX, INC. · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$70,000
Paid to lobbying firm
Support for H.R.3164/S.2426, Ensuring Community Access to Pharmacist Services Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOMERIEUX, INC. · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$70,000
Paid to lobbying firm
…ct, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Support for H.R.3164/S.2426, Ensuring Community Access to Pharmacist Services Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MCKESSON CORPORATION · lobbying firm or registrant: KOUNTOUPES DENHAM CARR & REID, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$60,000
Paid to lobbying firm
Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act. and S. 2426, Equitable Community Access to Pharmacist Services Act. Issues related to pharmacies and patient access.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER · lobbying firm or registrant: NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
…ng an exception to medication step-therapy protocol in specified cases). Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act. and S. 2426, Equitable Community Access to Pharmacist Services Act. Issues related to support for independent physician practices, community pharmacies, and community-base…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER · lobbying firm or registrant: NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Pharmacy
$30,000
Paid to lobbying firm
Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act. and S. 2426, Equitable Community Access to Pharmacist Services Act. Issues related to support for independent physician practices, community pharmacies, and community-base…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · lobbying firm or registrant: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$2,047,000
Spent on own lobbying
H.R. 879/S. 1640, the Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 1, the One Big Beautiful Bill Act; H.R. 3164/S. 2426, the Ensuring Community Access to Pharmacist Services Act; Draft legislation to amend title XVIII of the Social Security Act to modify the conversion factor up…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SURESCRIPTS · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$40,000
Paid to lobbying firm
S.2426, Equitable Community Access to Pharmacist Services Act, Entirety H.R.3164, Ensuring Community Access to Pharmacist Services Act, Entirety Data privacy Monitor…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing